Literature DB >> 35394532

An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.

Yonina R Murciano-Goroff1, Guilherme Harada1, Alexander Drilon1,2.   

Abstract

Central nervous system (CNS) metastases constitute a challenge for the design of anaplastic lymphoma kinase (ALK) fusion-positive lung cancer trials. The ASCEND-7 study of ceritinib demonstrates the feasibility of broadening CNS eligibility criteria to include symptomatic brain and leptomeningeal disease and highlights design features that contemporary trials will need to incorporate. See related article by Chow et al., p. 2506. ©2022 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35394532      PMCID： PMC9197849          DOI： 10.1158/1078-0432.CCR-22-0341

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  10 in total

1.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

2.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Authors:  Jean-Charles Soria; Daniel S W Tan; Rita Chiari; Yi-Long Wu; Luis Paz-Ares; Juergen Wolf; Sarayut L Geater; Sergey Orlov; Diego Cortinovis; Chong-Jen Yu; Maximillian Hochmair; Alexis B Cortot; Chun-Ming Tsai; Denis Moro-Sibilot; Rosario G Campelo; Tracey McCulloch; Paramita Sen; Margaret Dugan; Serafino Pantano; Fabrice Branle; Cristian Massacesi; Gilberto de Castro
Journal:  Lancet       Date:  2017-01-24       Impact factor: 79.321

3.  ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.

Authors:  Laura Q M Chow; Fabrice Barlesi; Erin M Bertino; Martin J van den Bent; Heather A Wakelee; Patrick Y Wen; Chao-Hua Chiu; Sergey Orlov; Rita Chiari; Margarita Majem; Mark McKeage; Chong-Jen Yu; Pilar Garrido; Felipe K Hurtado; Pilar Cazorla Arratia; Yuanbo Song; Fabrice Branle; Michael Shi; Dong-Wan Kim
Journal:  Clin Cancer Res       Date:  2022-06-13       Impact factor: 12.531

4.  Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  D Ross Camidge; Hye Ryun Kim; Myung-Ju Ahn; James Chih-Hsin Yang; Ji-Youn Han; Jong-Seok Lee; Maximilian J Hochmair; Jacky Yu-Chung Li; Gee-Chen Chang; Ki Hyeong Lee; Cesare Gridelli; Angelo Delmonte; Rosario Garcia Campelo; Dong-Wan Kim; Alessandra Bearz; Frank Griesinger; Alessandro Morabito; Enriqueta Felip; Raffaele Califano; Sharmistha Ghosh; Alexander Spira; Scott N Gettinger; Marcello Tiseo; Neeraj Gupta; Jeff Haney; David Kerstein; Sanjay Popat
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

5.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Authors:  Alice T Shaw; Todd M Bauer; Filippo de Marinis; Enriqueta Felip; Yasushi Goto; Geoffrey Liu; Julien Mazieres; Dong-Wan Kim; Tony Mok; Anna Polli; Holger Thurm; Anna M Calella; Gerson Peltz; Benjamin J Solomon
Journal:  N Engl J Med       Date:  2020-11-19       Impact factor: 91.245

6.  Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

Authors:  Anita Kort; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

7.  Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Authors:  Alice T Shaw; Enriqueta Felip; Todd M Bauer; Benjamin Besse; Alejandro Navarro; Sophie Postel-Vinay; Justin F Gainor; Melissa Johnson; Jorg Dietrich; Leonard P James; Jill S Clancy; Joseph Chen; Jean-François Martini; Antonello Abbattista; Benjamin J Solomon
Journal:  Lancet Oncol       Date:  2017-10-23       Impact factor: 41.316

Review 8.  Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.

Authors:  J Remon; Benjamin Besse
Journal:  Front Oncol       Date:  2018-04-11       Impact factor: 6.244

9.  Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.

Authors:  Adrienne Boire; Dieta Brandsma; Priscilla K Brastianos; Emilie Le Rhun; Manmeet Ahluwalia; Larry Junck; Michael Glantz; Morris D Groves; Eudocia Q Lee; Nancy Lin; Jeffrey Raizer; Roberta Rudà; Michael Weller; Martin J Van den Bent; Michael A Vogelbaum; Susan Chang; Patrick Y Wen; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2019-05-06       Impact factor: 12.300

10.  Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.

Authors:  Leora Horn; Ziping Wang; Gang Wu; Elena Poddubskaya; Tony Mok; Martin Reck; Heather Wakelee; Alberto A Chiappori; Dae Ho Lee; Valeriy Breder; Sergey Orlov; Irfan Cicin; Ying Cheng; Yunpeng Liu; Yun Fan; Jennifer G Whisenant; Yi Zhou; Vance Oertel; Kim Harrow; Chris Liang; Li Mao; Giovanni Selvaggi; Yi-Long Wu
Journal:  JAMA Oncol       Date:  2021-11-01       Impact factor: 31.777
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.